Literature DB >> 9827711

The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma.

Y Aoyagi1, O Isokawa, T Suda, M Watanabe, Y Suzuki, H Asakura.   

Abstract

BACKGROUND: The aim of this study was to elucidate the usefulness of measuring the fucosylation index (FI) of alpha-fetoprotein (AFP) before the initiation of therapy as a new prognostic indicator for patients with hepatocellular carcinoma (HCC).
METHODS: One hundred twelve patients with HCC who underwent transcatheter arterial embolization, chemoembolization, and/or percutaneous ethanol injection were examined in the current study. FI was determined by crossed immunoaffino-electrophoresis in the presence of Lens culinaris agglutinin.
RESULTS: When the tentative discriminating value of FI was set at 18%, the mean survival rate for the group whose FI was higher than 18% was significantly lower than that for the group whose FI was equal to or less than 18%, according to the generalized Wilcoxon test (P = 0.0117) and the log rank test (P = 0.0183). The survival rate for HCC patients with AFP concentrations of more than 200 ng/mL was also significantly lower than that for patients with AFP in the range of 21-200 ng/mL, according to the generalized Wilcoxon test (P = 0.0017) and the log rank test (P = 0.0018). When FI was combined with AFP concentration, a highly significant difference was observed between the group with FI >18% and AFP >200 ng/mL and another group with FI < or =18% and AFP < or =200 ng/mL, as determined by the generalized Wilcoxon test (P < 0.0001) and the log rank test (P = 0.0003). An analysis of multiple covariates in the prognostic factors with the Cox proportional hazards model showed that FI was one of the independent prognostic factors.
CONCLUSIONS: The current study indicates that measuring FI from sera before the initiation of treatment serves as a new prognostic factor and may improve prognostic estimates and appraisal of therapeutic outcomes for patients with HCC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827711

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment.

Authors:  Yasushi Tamura; Masato Igarashi; Takeshi Suda; Toshifumi Wakai; Yoshio Shirai; Takeji Umemura; Eiji Tanaka; Satoru Kakizaki; Hitoshi Takagi; Yoichi Hiasa; Morikazu Onji; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

3.  Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.

Authors:  Lucy Betesh; Mary Ann Comunale; Mengjun Wang; Hongyan Liang; Julie Hafner; Aykan Karabudak; Nasra H Giama; Catherine D Moser; Eiji Miyoshi; Lewis R Roberts; Timothy M Block; Anand Mehta
Journal:  Proteomics Clin Appl       Date:  2017-07-10       Impact factor: 3.494

Review 4.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

5.  Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma.

Authors:  Mary Ann Comunale; Lucy Rodemich-Betesh; Julie Hafner; Mengjun Wang; Pamela Norton; Adrian M Di Bisceglie; Timothy Block; Anand Mehta
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

6.  Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.

Authors:  Yasushi Tamura; Takeshi Suda; Shigeki Arii; Michio Sata; Fuminori Moriyasu; Hiroshi Imamura; Seiji Kawasaki; Namiki Izumi; Tadatoshi Takayama; Norihiro Kokudo; Masakazu Yamamoto; Hiroko Iijima; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2013-04-18       Impact factor: 3.199

7.  Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.

Authors:  Mengjun Wang; Ronald E Long; Mary Ann Comunale; Omer Junaidi; Jorge Marrero; Adrian M Di Bisceglie; Timothy M Block; Anand S Mehta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

8.  N-linked glycosylation of the liver cancer biomarker GP73.

Authors:  Pamela A Norton; Mary Ann Comunale; Jonathan Krakover; Lucy Rodemich; Natalie Pirog; Anthony D'Amelio; Ramila Philip; Anand S Mehta; Timothy M Block
Journal:  J Cell Biochem       Date:  2008-05-01       Impact factor: 4.429

9.  Identification of IgM as a contaminant in lectin-FLISA assays for HCC detection.

Authors:  Mengjun Wang; Mary Ann Comunale; Harmin Herrera; Lucy Betesh; Yuko Kono; Anand Mehta
Journal:  Biochem Biophys Res Commun       Date:  2016-05-13       Impact factor: 3.575

10.  Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm.

Authors:  Toshifumi Wakai; Yoshio Shirai; Takeshi Suda; Naoyuki Yokoyama; Jun Sakata; Pauldion V Cruz; Hirokazu Kawai; Yasunobu Matsuda; Masashi Watanabe; Yutaka Aoyagi; Katsuyoshi Hatakeyama
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.